{"id":"placebo-for-adalimumab","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish baseline efficacy and safety of an active drug (in this case, adalimumab). Any observed effects in placebo recipients are attributed to the placebo effect—psychological and physiological responses to the expectation of treatment rather than the drug itself. Placebos are essential for blinded, randomized controlled trials to isolate the true therapeutic benefit of the investigational or active agent.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:03.795Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 clinical trial for adalimumab (TNF-alpha inhibitor)"}]},"trialDetails":[{"nctId":"NCT06996652","phase":"PHASE2","title":"An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-04","conditions":"REM Sleep Behavior Disorder","enrollment":108},{"nctId":"NCT03153319","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2017-06-05","conditions":"Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI","enrollment":14},{"nctId":"NCT03412747","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2018-01-26","conditions":"Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis","enrollment":478},{"nctId":"NCT02586831","phase":"PHASE1, PHASE2","title":"Diabetes Islet Preservation Immune Treatment","status":"WITHDRAWN","sponsor":"Camillo Ricordi and Jay Skyler","startDate":"2024-06-01","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases","enrollment":""},{"nctId":"NCT05814627","phase":"PHASE3","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-06-15","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT02829424","phase":"PHASE4","title":"Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-23","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT03104400","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-04-27","conditions":"Psoriatic Arthritis","enrollment":1705},{"nctId":"NCT01385826","phase":"PHASE2, PHASE3","title":"Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2011-06-29","conditions":"Uveitis, Juvenile Arthritis","enrollment":34},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT04997733","phase":"PHASE3","title":"Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-09-22","conditions":"Crohn Disease","enrollment":150},{"nctId":"NCT02629159","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2015-12-01","conditions":"Rheumatoid Arthritis","enrollment":1629},{"nctId":"NCT06640517","phase":"PHASE3","title":"Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biocad","startDate":"2024-08-08","conditions":"Plaque Psoriasis","enrollment":140},{"nctId":"NCT03816397","phase":"PHASE4","title":"Adalimumab in JIA-associated Uveitis Stopping Trial","status":"COMPLETED","sponsor":"Nisha Acharya","startDate":"2020-03-15","conditions":"Uveitis, JIA","enrollment":87},{"nctId":"NCT03464136","phase":"PHASE3","title":"Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2018-03-29","conditions":"Crohn Disease","enrollment":386},{"nctId":"NCT05299242","phase":"PHASE2, PHASE3","title":"The Anti-Freaze-F Study- \"Anti-TNF for Treatment of Frozen Shoulder - a Feasibility Study\"","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-07-21","conditions":"Frozen Shoulder","enrollment":9},{"nctId":"NCT05090124","phase":"NA","title":"Experimental Medicine Studies of the Brain in Patients With Rheumatoid Arthritis REALISE","status":"COMPLETED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2022-11-04","conditions":"Rheumatoid Arthritis","enrollment":46},{"nctId":"NCT06062875","phase":"PHASE2","title":"Effects of TNF Blockade on Human BPH/LUTS","status":"RECRUITING","sponsor":"Endeavor Health","startDate":"2024-01-24","conditions":"Benign Prostatic Hyperplasia (BPH)","enrollment":70},{"nctId":"NCT05640245","phase":"PHASE2","title":"Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"MoonLake Immunotherapeutics AG","startDate":"2022-12-13","conditions":"Arthritis, Psoriatic","enrollment":207},{"nctId":"NCT03180957","phase":"PHASE2","title":"Repurposing Anti-TNF for Treating Dupuytren's Disease","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2016-03-02","conditions":"Dupuytren's Disease","enrollment":140},{"nctId":"NCT05322473","phase":"PHASE2","title":"Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"MoonLake Immunotherapeutics AG","startDate":"2022-04-25","conditions":"Hidradenitis Suppurativa","enrollment":234},{"nctId":"NCT04988308","phase":"PHASE2","title":"A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-12","conditions":"Hidradenitis Suppurativa","enrollment":151},{"nctId":"NCT02760407","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2016-06-06","conditions":"Rheumatoid Arthritis","enrollment":1648},{"nctId":"NCT05871086","phase":"PHASE2, PHASE3","title":"Coenzyme Q10 in Juvenile Idiopathic Arthritis Patients","status":"UNKNOWN","sponsor":"Nourhan Elsherif","startDate":"2023-05-01","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT05020730","phase":"PHASE2","title":"Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa","status":"UNKNOWN","sponsor":"Phoenicis Therapeutics","startDate":"2022-05-05","conditions":"Hidradenitis Suppurativa","enrollment":50},{"nctId":"NCT04115748","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2019-12-03","conditions":"Psoriatic Arthritis","enrollment":67},{"nctId":"NCT02332590","phase":"PHASE3","title":"Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01-28","conditions":"Rheumatoid Arthritis","enrollment":369},{"nctId":"NCT01373151","phase":"PHASE2","title":"Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2011-06","conditions":"Rheumatoid Arthritis","enrollment":418},{"nctId":"NCT02471118","phase":"PHASE2","title":"Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA)","status":"COMPLETED","sponsor":"CARE ARTHRITIS LTD.","startDate":"2015-03","conditions":"Osteoarthritis, Knee","enrollment":62},{"nctId":"NCT02694523","phase":"PHASE3","title":"BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03","conditions":"Psoriasis","enrollment":684},{"nctId":"NCT02207231","phase":"PHASE3","title":"A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-11-26","conditions":"Psoriasis","enrollment":837},{"nctId":"NCT02207244","phase":"PHASE3","title":"A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-11-03","conditions":"Psoriasis","enrollment":992},{"nctId":"NCT03823391","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-03-27","conditions":"Rheumatoid Arthritis (RA)","enrollment":48},{"nctId":"NCT01166282","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-09","conditions":"Enthesitis Related Arthritis (ERA)","enrollment":46},{"nctId":"NCT01468233","phase":"PHASE3","title":"Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-11","conditions":"Hidradenitis Suppurativa (HS)","enrollment":326},{"nctId":"NCT01468207","phase":"PHASE3","title":"Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-11","conditions":"Hidradenitis Suppurativa (HS)","enrollment":307},{"nctId":"NCT01124838","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-08","conditions":"Uveitis","enrollment":261},{"nctId":"NCT01138657","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Patients With Active Uveitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-08","conditions":"Uveitis","enrollment":239},{"nctId":"NCT01064856","phase":"PHASE3","title":"Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-02","conditions":"Peripheral Spondyloarthritis","enrollment":165},{"nctId":"NCT01716039","phase":"PHASE2","title":"Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)","status":"TERMINATED","sponsor":"Alimentiv Inc.","startDate":"2013-06","conditions":"Ulcerative Colitis","enrollment":22},{"nctId":"NCT04643483","phase":"PHASE3","title":"A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease","status":"WITHDRAWN","sponsor":"UCB Biopharma SRL","startDate":"2021-06","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT02889796","phase":"PHASE3","title":"Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-08-30","conditions":"Rheumatoid Arthritis","enrollment":1759},{"nctId":"NCT01893996","phase":"PHASE4","title":"Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease","status":"COMPLETED","sponsor":"Jonathan Graf","startDate":"2013-07","conditions":"Rheumatoid Arthritis, Cardiovascular Disease","enrollment":63},{"nctId":"NCT02065570","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-05-01","conditions":"Crohn's Disease","enrollment":514},{"nctId":"NCT02065622","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-03-27","conditions":"Ulcerative Colitis (UC)","enrollment":952},{"nctId":"NCT01197144","phase":"NA","title":"Pain Modulation in Rheumatoid Arthritis (RA) - Influence of Adalimumab","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2010-10","conditions":"Arthritis, Rheumatoid, Pain, Fatigue","enrollment":70},{"nctId":"NCT02983227","phase":"PHASE2","title":"A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-11-30","conditions":"Rheumatoid Arthritis","enrollment":496},{"nctId":"NCT02833350","phase":"PHASE2","title":"Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-09-09","conditions":"Rheumatoid Arthritis","enrollment":578},{"nctId":"NCT02808975","phase":"PHASE4","title":"Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-07-18","conditions":"Hidradenitis Suppurativa (HS)","enrollment":206},{"nctId":"NCT01695239","phase":"PHASE3","title":"A Study of Ixekizumab in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-12","conditions":"Psoriasis, Arthritic","enrollment":417},{"nctId":"NCT01029847","phase":"PHASE4","title":"Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2009-12","conditions":"Spondyloarthritis","enrollment":49},{"nctId":"NCT02499783","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-08-17","conditions":"Crohn's Disease","enrollment":205},{"nctId":"NCT01500278","phase":"PHASE4","title":"Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2011-12","conditions":"Rheumatoid Arthritis","enrollment":915},{"nctId":"NCT02187055","phase":"PHASE4","title":"An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-08","conditions":"Rhematoid Arthritis","enrollment":1152},{"nctId":"NCT02862574","phase":"PHASE2","title":"Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2016-12-15","conditions":"Rheumatoid Arthritis","enrollment":15},{"nctId":"NCT02015793","phase":"PHASE2","title":"Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-12","conditions":"Crohn's Disease","enrollment":30},{"nctId":"NCT01808118","phase":"PHASE3","title":"Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-04-16","conditions":"Axial Spondyloarthritis","enrollment":673},{"nctId":"NCT01553058","phase":"PHASE4","title":"Vascular Inflammation in Psoriasis Trial (The VIP Trial)","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2012-07","conditions":"Psoriasis, Cardiovascular Disease","enrollment":97},{"nctId":"NCT02019472","phase":"PHASE3","title":"A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-04-04","conditions":"Arthritis, Rheumatoid","enrollment":559},{"nctId":"NCT02150473","phase":"PHASE3","title":"The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cartilage in (RA) Patients","status":"TERMINATED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2014-10","conditions":"Rheumatoid Arthritis","enrollment":21},{"nctId":"NCT01251614","phase":"PHASE3","title":"A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-12","conditions":"Plaque Psoriasis","enrollment":114},{"nctId":"NCT02437253","phase":"PHASE1, PHASE2","title":"Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2015-05","conditions":"Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type VI","enrollment":2},{"nctId":"NCT02349451","phase":"PHASE2","title":"A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-04-28","conditions":"Psoriatic Arthritis","enrollment":240},{"nctId":"NCT01483599","phase":"PHASE2","title":"A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Janssen Inc.","startDate":"2011-11-10","conditions":"Psoriasis","enrollment":293},{"nctId":"NCT01764997","phase":"PHASE3","title":"An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate","status":"TERMINATED","sponsor":"Sanofi","startDate":"2013-04","conditions":"Rheumatoid Arthritis","enrollment":776},{"nctId":"NCT02016482","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-01","conditions":"Nail Psoriasis, Plaque Psoriasis","enrollment":217},{"nctId":"NCT01899755","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-07-10","conditions":"Psoriasis","enrollment":45},{"nctId":"NCT00480272","phase":"PHASE4","title":"Prospective Study on Intensive Early Rheumatoid Arthritis Treatment","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2007-05","conditions":"Rheumatoid Arthritis","enrollment":251},{"nctId":"NCT02643654","phase":"PHASE2","title":"MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB","status":"COMPLETED","sponsor":"Evangelos J. Giamarellos-Bourboulis, M.D.","startDate":"2015-12","conditions":"Hidradenitis Suppurativa","enrollment":20},{"nctId":"NCT01722214","phase":"PHASE4","title":"Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis","status":"COMPLETED","sponsor":"Innovaderm Research Inc.","startDate":"2012-11","conditions":"Psoriasis, Vascular Inflammation, Coronary Atherosclerosis","enrollment":107},{"nctId":"NCT00595413","phase":"PHASE2","title":"Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2007-09","conditions":"Rheumatoid Arthritis","enrollment":311},{"nctId":"NCT00660647","phase":"PHASE3","title":"Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2007-09","conditions":"Arthritis, Rheumatoid","enrollment":180},{"nctId":"NCT00298272","phase":"PHASE2","title":"Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Biogen","startDate":"2006-05","conditions":"Rheumatoid Arthritis","enrollment":54},{"nctId":"NCT01295814","phase":"PHASE3","title":"Efficacy Study of Adalimumab to Treat Interstitial Cystitis","status":"COMPLETED","sponsor":"ICStudy, LLC","startDate":"2011-03","conditions":"Interstitial Cystitis","enrollment":43},{"nctId":"NCT01870284","phase":"PHASE3","title":"Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)","status":"WITHDRAWN","sponsor":"Eli Lilly and Company","startDate":"2014-07","conditions":"Spondylitis, Ankylosing","enrollment":""},{"nctId":"NCT00853099","phase":"PHASE3","title":"A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-02","conditions":"Ulcerative Colitis","enrollment":274},{"nctId":"NCT02097264","phase":"PHASE2","title":"A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2014-09","conditions":"Inflammation, Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT02092961","phase":"PHASE2","title":"Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2011-02","conditions":"Rheumatoid Arthritis","enrollment":198},{"nctId":"NCT02132234","phase":"PHASE4","title":"Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis","status":"UNKNOWN","sponsor":"Jagiellonian University","startDate":"2013-06","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis","enrollment":100},{"nctId":"NCT01264770","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2011-01","conditions":"Rheumatoid Arthritis","enrollment":644},{"nctId":"NCT01283971","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2011-05","conditions":"Rheumatoid Arthritis","enrollment":96},{"nctId":"NCT01510548","phase":"PHASE3","title":"ADALISKIAS: Adalimumab for Acute Disc Prolapse","status":"UNKNOWN","sponsor":"Kuopio University Hospital","startDate":"2007-03","conditions":"Disc Prolapse, Pain","enrollment":90},{"nctId":"NCT00195663","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2000-12","conditions":"Early Rheumatoid Arthritis","enrollment":799},{"nctId":"NCT00274352","phase":"PHASE2","title":"A Study of Adalimumab to Treat Sarcoidosis of the Skin","status":"COMPLETED","sponsor":"Pariser, Robert J., M.D.","startDate":"2006-09","conditions":"Sarcoidosis","enrollment":16},{"nctId":"NCT01119859","phase":"PHASE4","title":"A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-05","conditions":"Rheumatoid Arthritis","enrollment":326},{"nctId":"NCT00853385","phase":"PHASE3","title":"A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-05","conditions":"Rheumatoid Arthritis","enrollment":717},{"nctId":"NCT00550446","phase":"PHASE2","title":"A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-09","conditions":"Arthritis, Rheumatoid","enrollment":386},{"nctId":"NCT00796705","phase":"PHASE4","title":"Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-11","conditions":"Rheumatoid Arthritis","enrollment":13},{"nctId":"NCT00870467","phase":"PHASE3","title":"A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":334},{"nctId":"NCT00597623","phase":"PHASE3","title":"Efficacy Study of an Anti-Tumor Necrosis Factor (TNF) Alpha Agent in Patients With Hand Osteoarthritis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-01","conditions":"Hand Osteoarthritis","enrollment":84},{"nctId":"NCT00305539","phase":"PHASE3","title":"HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2006-05","conditions":"Giant Cell Arteritis","enrollment":69},{"nctId":"NCT00420927","phase":"PHASE4","title":"Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-12","conditions":"Rheumatoid Arthritis","enrollment":1032},{"nctId":"NCT00736983","phase":"PHASE3","title":"Adalimumab in Combination With Ciprofloxacin/Placebo Treatment of Perianal Fistulas in Crohn's","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2008-09","conditions":"Crohn's Disease With Perianal Fistulas","enrollment":76},{"nctId":"NCT00445432","phase":"PHASE2, PHASE3","title":"A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-03","conditions":"Crohn's Disease","enrollment":82},{"nctId":"NCT01181570","phase":"PHASE4","title":"Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"Innovaderm Research Inc.","startDate":"2010-09","conditions":"Psoriasis, Sleep Apnea, Obstructive","enrollment":20},{"nctId":"NCT00195702","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.","status":"COMPLETED","sponsor":"Abbott","startDate":"2000-02","conditions":"Rheumatoid Arthritis","enrollment":619},{"nctId":"NCT00048542","phase":"PHASE3","title":"Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-09","conditions":"Arthritis, Juvenile Idiopathic","enrollment":171},{"nctId":"NCT01405326","phase":"PHASE4","title":"REstore Working Ability in RheumatoiD Arthritis","status":"UNKNOWN","sponsor":"The Rheumatological Center of Helsinki","startDate":"2011-05","conditions":"Rheumatoid Arthritis","enrollment":160},{"nctId":"NCT00445939","phase":"PHASE2, PHASE3","title":"A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-02","conditions":"Crohn's Disease","enrollment":90},{"nctId":"NCT00918255","phase":"PHASE2","title":"Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"Abbott","startDate":"2009-04","conditions":"Hidradenitis Suppurativa","enrollment":154},{"nctId":"NCT00408629","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-11","conditions":"Ulcerative Colitis","enrollment":518}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["placebo"],"phase":"phase_3","status":"active","brandName":"Placebo for Adalimumab","genericName":"Placebo for Adalimumab","companyName":"Janssen Scientific Affairs, LLC","companyId":"janssen-scientific-affairs-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in Phase 3 clinical trial for adalimumab (TNF-alpha inhibitor).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}